vs
Cue Biopharma, Inc.（CUE）与RIVERVIEW BANCORP INC（RVSB）财务数据对比。点击上方公司名可切换其他公司
Cue Biopharma, Inc.的季度营收约是RIVERVIEW BANCORP INC的1.6倍（$21.9M vs $14.0M），RIVERVIEW BANCORP INC净利率更高（9.8% vs 7.2%，领先2.6%），Cue Biopharma, Inc.同比增速更快（1292.3% vs 10.4%），过去两年Cue Biopharma, Inc.的营收复合增速更高（257.5% vs 24.6%）
Cue Biopharma是一家临床阶段生物技术企业，专注于开发针对癌症、自身免疫性疾病和炎症疾病的新型靶向免疫疗法，其专有平台可精准调节T细胞活性，主要业务覆盖北美地区，与全球药企合作推进核心候选产品的临床试验。
Riverview Bancorp Inc.是一家总部位于美国的银行控股公司，主营个人与商业银行业务，服务覆盖太平洋西北地区，提供存款、消费贷款、住房抵押贷款、商业信贷及小企业金融等产品，服务零售客户与本地企业群体。
CUE vs RVSB — 直观对比
营收规模更大
CUE
是对方的1.6倍
$14.0M
营收增速更快
CUE
高出1281.9%
10.4%
净利率更高
RVSB
高出2.6%
7.2%
两年增速更快
CUE
近两年复合增速
24.6%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $21.9M | $14.0M |
| 净利润 | $1.6M | $1.4M |
| 毛利率 | — | — |
| 营业利润率 | 9.0% | 12.4% |
| 净利率 | 7.2% | 9.8% |
| 营收同比 | 1292.3% | 10.4% |
| 净利润同比 | 116.7% | 11.8% |
| 每股收益（稀释后） | $0.05 | $0.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CUERVSB
| Q4 25 | $21.9M | $14.0M | ||
| Q3 25 | $2.1M | $13.6M | ||
| Q2 25 | $3.0M | $13.3M | ||
| Q1 25 | $421.0K | $12.9M | ||
| Q4 24 | $1.6M | $12.7M | ||
| Q3 24 | $3.3M | $12.8M | ||
| Q2 24 | $2.7M | $12.2M | ||
| Q1 24 | $1.7M | $9.0M |
净利润CUERVSB
| Q4 25 | $1.6M | $1.4M | ||
| Q3 25 | $-7.4M | $1.1M | ||
| Q2 25 | $-8.5M | $1.2M | ||
| Q1 25 | $-12.3M | $1.1M | ||
| Q4 24 | — | $1.2M | ||
| Q3 24 | $-8.7M | $1.6M | ||
| Q2 24 | $-10.2M | $966.0K | ||
| Q1 24 | $-12.3M | $-3.0M |
营业利润率CUERVSB
| Q4 25 | 9.0% | 12.4% | ||
| Q3 25 | -353.4% | 10.2% | ||
| Q2 25 | -292.3% | 11.7% | ||
| Q1 25 | -2921.4% | 11.3% | ||
| Q4 24 | — | 12.4% | ||
| Q3 24 | -264.2% | 15.5% | ||
| Q2 24 | -390.6% | 10.0% | ||
| Q1 24 | -737.8% | -47.5% |
净利率CUERVSB
| Q4 25 | 7.2% | 9.8% | ||
| Q3 25 | -346.6% | 8.1% | ||
| Q2 25 | -287.1% | 9.2% | ||
| Q1 25 | -2911.4% | 8.9% | ||
| Q4 24 | — | 9.7% | ||
| Q3 24 | -259.6% | 12.2% | ||
| Q2 24 | -382.7% | 7.9% | ||
| Q1 24 | -719.1% | -34.7% |
每股收益（稀释后）CUERVSB
| Q4 25 | $0.05 | $0.07 | ||
| Q3 25 | $-0.07 | $0.05 | ||
| Q2 25 | $-0.09 | $0.06 | ||
| Q1 25 | $-0.17 | $0.05 | ||
| Q4 24 | — | $0.06 | ||
| Q3 24 | $-0.17 | $0.07 | ||
| Q2 24 | $-0.20 | $0.05 | ||
| Q1 24 | $-0.25 | $-0.14 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $27.1M | $28.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $26.4M | $164.2M |
| 总资产 | $42.2M | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CUERVSB
| Q4 25 | $27.1M | $28.6M | ||
| Q3 25 | $11.7M | $32.8M | ||
| Q2 25 | $27.5M | $34.2M | ||
| Q1 25 | $13.1M | $29.4M | ||
| Q4 24 | $22.5M | $25.3M | ||
| Q3 24 | $32.4M | $31.0M | ||
| Q2 24 | $30.0M | $27.8M | ||
| Q1 24 | $41.0M | $23.6M |
总债务CUERVSB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $1.0M | — | ||
| Q2 24 | $2.0M | — | ||
| Q1 24 | $3.0M | — |
股东权益CUERVSB
| Q4 25 | $26.4M | $164.2M | ||
| Q3 25 | $13.2M | $163.5M | ||
| Q2 25 | $18.2M | $162.0M | ||
| Q1 25 | $6.6M | $160.0M | ||
| Q4 24 | $17.5M | $158.3M | ||
| Q3 24 | $25.4M | $160.8M | ||
| Q2 24 | $21.6M | $155.9M | ||
| Q1 24 | $30.0M | $155.6M |
总资产CUERVSB
| Q4 25 | $42.2M | $1.5B | ||
| Q3 25 | $31.6M | $1.5B | ||
| Q2 25 | $40.7M | $1.5B | ||
| Q1 25 | $22.3M | $1.5B | ||
| Q4 24 | $32.2M | $1.5B | ||
| Q3 24 | $44.8M | $1.5B | ||
| Q2 24 | $42.3M | $1.5B | ||
| Q1 24 | $54.0M | $1.5B |
负债/权益比CUERVSB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.04× | — | ||
| Q2 24 | 0.09× | — | ||
| Q1 24 | 0.10× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.1M | $-506.0K |
| 自由现金流经营现金流 - 资本支出 | — | $-736.0K |
| 自由现金流率自由现金流/营收 | — | -5.2% |
| 资本支出强度资本支出/营收 | 0.0% | 1.6% |
| 现金转化率经营现金流/净利润 | -0.68× | -0.37× |
| 过去12个月自由现金流最近4个季度 | — | $20.4M |
8季度趋势，按日历期对齐
经营现金流CUERVSB
| Q4 25 | $-1.1M | $-506.0K | ||
| Q3 25 | $-9.0M | $16.8M | ||
| Q2 25 | $-3.4M | $-697.0K | ||
| Q1 25 | $-8.2M | $8.3M | ||
| Q4 24 | $-36.3M | $2.2M | ||
| Q3 24 | $-7.5M | $764.0K | ||
| Q2 24 | $-10.0M | $5.4M | ||
| Q1 24 | $-9.8M | $12.8M |
自由现金流CUERVSB
| Q4 25 | — | $-736.0K | ||
| Q3 25 | — | $16.4M | ||
| Q2 25 | $-3.4M | $-773.0K | ||
| Q1 25 | $-8.3M | $5.6M | ||
| Q4 24 | $-36.4M | $1.9M | ||
| Q3 24 | $-7.5M | $-1.4M | ||
| Q2 24 | $-10.0M | $5.3M | ||
| Q1 24 | $-9.8M | $7.1M |
自由现金流率CUERVSB
| Q4 25 | — | -5.2% | ||
| Q3 25 | — | 120.1% | ||
| Q2 25 | -116.5% | -5.8% | ||
| Q1 25 | -1976.7% | 43.1% | ||
| Q4 24 | -2309.3% | 15.0% | ||
| Q3 24 | -225.7% | -11.3% | ||
| Q2 24 | -376.2% | 43.7% | ||
| Q1 24 | -573.0% | 79.0% |
资本支出强度CUERVSB
| Q4 25 | 0.0% | 1.6% | ||
| Q3 25 | 0.0% | 2.9% | ||
| Q2 25 | 0.9% | 0.6% | ||
| Q1 25 | 35.6% | 21.0% | ||
| Q4 24 | 4.2% | 2.4% | ||
| Q3 24 | 0.0% | 17.3% | ||
| Q2 24 | 0.4% | 0.9% | ||
| Q1 24 | 3.2% | 62.0% |
现金转化率CUERVSB
| Q4 25 | -0.68× | -0.37× | ||
| Q3 25 | — | 15.25× | ||
| Q2 25 | — | -0.57× | ||
| Q1 25 | — | 7.20× | ||
| Q4 24 | — | 1.79× | ||
| Q3 24 | — | 0.49× | ||
| Q2 24 | — | 5.63× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CUE
| Immuno Scape Collaboration And License Agreement | $9.5M | 43% |
| BI Collaboration And License Agreement | $8.1M | 37% |
| Other | $4.3M | 20% |
RVSB
暂无分部数据
